Arleen A Leibowitz1, Katherine Desmond. 1. Both authors are with the Department of Public Policy, Luskin School of Public Affairs, University of California Los Angeles.
Abstract
OBJECTIVES: We sought to identify people living with HIV/AIDS from Medicare and Medicaid claims data to estimate Medicaid costs for treating HIV/AIDS in California. We also examined how alternate methods of identifying the relevant sample affect estimates of per capita costs. METHODS: We analyzed data on Californians enrolled in Medicaid with an HIV/AIDS diagnosis reported in 2007 Medicare or Medicaid claims data. We compared alternative selection criteria by examining use of antiretroviral drugs, HIV-specific monitoring tests, and medical costs. We compared the final sample and average costs with other estimates of the size of California's HIV/AIDS population covered by Medicaid in 2007 and their average treatment costs. RESULTS: Eighty-seven percent (18,290) of potentially identifiable HIV-positive individuals satisfied at least 1 confirmation criterion. Nearly 80% of confirmed observations had claims for HIV-specific tests, compared with only 3% of excluded cases. Female Medicaid recipients were particularly likely to be miscoded as having HIV. Medicaid treatment spending for Californians with HIV averaged $33,720 in 2007. CONCLUSIONS: The proposed algorithm displays good internal and external validity. Accurately identifying HIV cases in claims data is important to avoid drawing biased conclusions and is necessary in setting appropriate HIV managed-care capitation rates.
OBJECTIVES: We sought to identify people living with HIV/AIDS from Medicare and Medicaid claims data to estimate Medicaid costs for treating HIV/AIDS in California. We also examined how alternate methods of identifying the relevant sample affect estimates of per capita costs. METHODS: We analyzed data on Californians enrolled in Medicaid with an HIV/AIDS diagnosis reported in 2007 Medicare or Medicaid claims data. We compared alternative selection criteria by examining use of antiretroviral drugs, HIV-specific monitoring tests, and medical costs. We compared the final sample and average costs with other estimates of the size of California's HIV/AIDS population covered by Medicaid in 2007 and their average treatment costs. RESULTS: Eighty-seven percent (18,290) of potentially identifiable HIV-positive individuals satisfied at least 1 confirmation criterion. Nearly 80% of confirmed observations had claims for HIV-specific tests, compared with only 3% of excluded cases. Female Medicaid recipients were particularly likely to be miscoded as having HIV. Medicaid treatment spending for Californians with HIV averaged $33,720 in 2007. CONCLUSIONS: The proposed algorithm displays good internal and external validity. Accurately identifying HIV cases in claims data is important to avoid drawing biased conclusions and is necessary in setting appropriate HIV managed-care capitation rates.
Authors: Thomas S Rector; Steven L Wickstrom; Mona Shah; N Thomas Greeenlee; Paula Rheault; Jeannette Rogowski; Vicki Freedman; John Adams; José J Escarce Journal: Health Serv Res Date: 2004-12 Impact factor: 3.402
Authors: Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark Journal: MMWR Recomm Rep Date: 2006-09-22
Authors: Kelly A Gebo; John A Fleishman; Richard Conviser; James Hellinger; Fred J Hellinger; Joshua S Josephs; Philip Keiser; Paul Gaist; Richard D Moore Journal: AIDS Date: 2010-11-13 Impact factor: 4.177
Authors: Janet M Blair; Jennifer L Fagan; Emma L Frazier; Ann Do; Heather Bradley; Eduardo E Valverde; Ad McNaghten; Linda Beer; Shuyan Zhang; Ping Huang; Christine L Mattson; Mark S Freedman; Christopher H Johnson; Catherine C Sanders; Kathryn E Spruit-McGoff; James D Heffelfinger; Jacek Skarbinski Journal: MMWR Suppl Date: 2014-06-20
Authors: Yiyang Liu; Khairul A Siddiqi; Robert L Cook; Jiang Bian; Patrick J Squires; Elizabeth A Shenkman; Mattia Prosperi; Dushyantha T Jayaweera Journal: Methods Inf Med Date: 2021-09-30 Impact factor: 1.800
Authors: Adil Faqih; Amit G Singal; Hannah M Fullington; Benjamin Hewitt; Ezra Burstein; Purva Gopal; Annika Wylie; John Abrams; Caitlin C Murphy Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: John A Fleishman; Anne K Monroe; Cindy C Voss; Richard D Moore; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2016-08-01 Impact factor: 3.731
Authors: Raphael J Landovitz; Katherine A Desmond; Jennifer L Gildner; Arleen A Leibowitz Journal: AIDS Patient Care STDS Date: 2016-09 Impact factor: 5.078
Authors: Seyram A Butame; Jessica M De Leon; Sung-Jae Lee; Sylvie Naar; Leah Genn; Tyra Dark; Bill G Kapogiannis Journal: Eval Health Prof Date: 2021-03-04 Impact factor: 2.329
Authors: Marina Treskova; Alexander Kuhlmann; Johannes Bogner; Martin Hower; Hans Heiken; Hans-Jürgen Stellbrink; Jörg Mahlich; Johann-Matthias Graf von der Schulenburg; Matthias Stoll Journal: Medicine (Baltimore) Date: 2016-06 Impact factor: 1.889